Dr. Pinato Discusses Intra-tumor Heterogeneity in Primary and Metastatic HCC

(1:54)

Dr. Pinato on Study of Immune-Tolerogenic Pathways in Primary and Metastatic HCC

(2:2)

Dr. Pinato on PD-L1 Testing in HCC

(1:57)

Dr. Pinato Discusses Pheochromocytomas and Paragangliomas

(1:38)

mRNA vaccine approaches to cancer treatment - Dr David Pinato (Part 2 of 2)

(24:18)

Dr. Pinato on Study of Sorafenib in Pretreated Patients With HCC

(1:27)

APGCS 2022 | Dr. David Pinato

(43)

Dr. Pinato on Molecular Characterization of Tumor Microenvironment in NETs

(3:15)

[HR]Prof. David James Pinato, Topic: Immunotherapy in HCC

(33:20)

Today Immunotherapy can cure even fourth stage cancer: Dr Dattatreyudu Nori

(8:46)

Peanut Butter Making in Taiwan / 花生醬製作 - Taiwanese Food

(12:22)

Immune Therapy in Hepatocellular Carcinoma

(47:42)

COVID-19 and Its Mysterious Smells

(11:40)

Immunotherapy and the side effects

(6:47)

HCC pathophysiology, treatments and mechanisms

(4:11)

Covid-19 and Increased Cancer Risk

(4:4)

Discovering the PD-1 Checkpoint: Winners of the 2014 William B. Coley Award for Tumor Immunology

(3:40)

Hepatocellular Carcinoma: Expert Insights From the Patient CaseBook

(1:26:24)

Hepatocellular Carcinoma Lecture Simplified

(15:39)

Impressions from the Liver Cancer Summit 2023 David Pinato

(41)

BREAKTHROUGH cancer treatment could be on the horizon with mRNA vaccine

(7:19)

Antibiotics impact outcomes with pembrolizumab in NSCLC patients

(2:3)

PRIME-HCC: ipilimumab and nivolumab in liver cancer

(1:)

'Concerning' revelation: breast cancer survivors are 86% more likely to develop other cancers

(7:26)

PD-1/VEGFR blockade for liver cancer

(1:23)

Long-term outcomes and complications in patients who have recovered from COVID-19

(13:29)

This RARE tumor causes high blood pressure!

(1:)

Evaluating real-world efficacy of durvalumab and tremelimumab in HCC

(1:2)

COVID-19 and cancer outcomes in the UK

(3:22)

Metastatic spread of Cancer to the Spine #shorts #medical #doctor

(13)